Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T ...

18 October 2026 · By · Wire by Fusion42

Published

18 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at local3news.com →

◆ Verified

Fusion42 · 18 October 2026 · Fusion42 review

Vivacta Bio and Grit Bio received FDA orphan drug designation for their in vivo CAR-T therapy, GT801, targeting autoimmune hemolytic anemia, advancing novel treatments for rare autoimmune diseases.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 17 Oct 2026 and 18 Oct 2026.

◆ ◆ The Wire takeaway

You have a regulatory path clearing to develop rare autoimmune disease treatments with CAR-T methods, opening a less competitive niche and faster approval chances. Act quickly to pursue orphan drug status for innovative therapies beyond mainstream immune indications.

◆ Coverage

2 sources · first reported 17 Oct 2026 · latest 18 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfdaorphan-drugautoimmune-diseasecar-t-therapyrare-disease